349 studies found for:    "Myelofibrosis"
Show Display Options
Rank Status Study
21 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
22 Active, not recruiting Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   Myeloid Malignancies
Intervention: Drug: imetelstat sodium
23 Active, not recruiting
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
24 Terminated
Has Results
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
25 Completed
Has Results
CEP-701 for PH-negative Myelofibrosis
Conditions: Leukemia;   Myelofibrosis
Intervention: Drug: CEP-701
26 Active, not recruiting
Has Results
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Condition: Myelofibrosis
Interventions: Drug: INC424/INCB018424;   Drug: Best Available Therapy (BAT)
27 Not yet recruiting JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: enzyme inhibitor therapy;   Drug: ruxolitinib phosphate;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: busulfan;   Drug: melphalan;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
28 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
29 Active, not recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
30 Completed Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cyclophosphamide;   Drug: busulfan;   Drug: tacrolimus;   Drug: methotrexate;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: pharmacogenomic studies;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
31 Completed
Has Results
A Phase II Study of CC-5013 in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: CC-5013
32 Completed
Has Results
Ph II Study of Azacitidine in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Azacitidine
33 Recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
34 Completed A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: TG101348
35 Completed Efficacy and Safety of GS-6624 in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: GS-6624;   Drug: Ruxolitinib
36 Completed Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
37 Terminated
Has Results
Azacitidine in Treating Patients With Myelofibrosis
Conditions: Chronic Myeloproliferative Disorders;   Secondary Myelofibrosis
Intervention: Drug: azacitidine
38 Active, not recruiting CEP-701 (Lestaurtinib) in Myelofibrosis
Conditions: Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
39 Recruiting Lenalidomide for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Lenalidomide;   Drug: Prednisone
40 Active, not recruiting Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years